

3. Claims 15-28, drawn to a method of identifying an HBP antagonist, classified in Class 435, subclass 7.1.
4. Claims 29-31 and 38-41, drawn to a method of determining if a mammal produces HBP, classified in Class 435, subclass 7.1; and Class 436, subclass 63.
5. Claims 32-37, drawn to a kit comprising an HBP antagonist wherein the antagonist is aprotinin, classified in Class 435, subclass 810; and Class 530, subclass 380.
6. Claims 32-37, drawn to a kit comprising an HBP antagonist wherein the antagonist is aprotinin, classified in Class 435, subclass 810; and Class 530, subclass 387.9.


It is further asserted that the application contains claims directed to the following patentably distinct species of the claimed Inventions I and II: wherein the disorder is systemic inflammatory response syndrome, ischemia reperfusion, anaphylaxis, allograft rejection or adult respiratory distress syndrome. It is asserted that these species are distinct because the pathological conditions differ in etiologies and therapeutic endpoints and thus represent patentably distinct subject matter. The Examiner asserts that the Applicant is required under 35 U.S.C. §121 to elect a single disclosed species for prosecution on the merits to which the claims shall be retired if no generic claims is finally held to be allowable.

In response, Applicants elect, with traverse, the claims of Group II, claims 1-8 and 12-14. Applicants furthermore elect the species, systemic inflammatory response syndrome. All of the elected claims cover the elected species.

In view of the above, it is respectfully submitted that all claims are in condition for examination. Early action to that end is respectfully requested. The Examiner is hereby invited to contact the undersigned by telephone at (914) 712-0093 if there are any questions concerning this response or application.

Respectfully submitted,

Date: 11/17/00

A handwritten signature in cursive script, reading "Cheryl H. Agris", written over a horizontal line.

Cheryl H. Agris, Reg. No. 34,086

Counsel for

Novo Nordisk of North America, Inc.

405 Lexington Avenue, Suite 6400

New York, NY 10174-6201